Hong Yu Ah, Hwang Hyeon Seok, Sul Hae Joung, Kim Suk Young, Chang Yoon Kyung
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Daejeon St. Mary's Hospital 64, Daeheung-ro, Jung-gu, Daejeon, 34943, Republic of Korea.
Department of Pathology, College of Medicine, The Catholic University of Korea, Daejeon St. Mary's Hospital, 64, Daeheung-ro, Jung-gu, Daejeon, 34943, Republic of Korea.
BMC Nephrol. 2017 Sep 21;18(1):299. doi: 10.1186/s12882-017-0715-2.
Kidney transplantation (KT) is the treatment option for patients with end stage renal disease (ESRD) to prolong survival and improve quality of life. Although the use of potent immunosuppressive agents increases graft survival in kidney transplantation recipients (KTRs), it may lead to the development of malignancy, including transitional cell carcinoma (TCC). TCC developing in the pelvis of graft kidney is very rare in KTRs.
A 40-year-old male visited hospital with complaints of nausea, vomiting and gross hematuria. Eleven years ago, he was diagnosed ESRD of unknown origin, and received a living related KT from his father 1 year later. Radiologic findings showed a huge polypoid mass in the pelvis of graft kidney with pelvo-calyceal dilation and a 3.3 cm-sized nodule in aortocaval chain and a 2.5 cm-sized nodule in right iliac chain as TCC stage IV. Sonography-guided percutaneous needle biopsy of pelvis mass in the graft kidney revealed a low grade urothelial cell carcinoma. Radical graft nephroureterectomy was performed and histopathological diagnosis confirmed as a low grade urothelial carcinoma of graft pelvis and ureter lumen, which invaded to perirenal fat and renal parenchyma with lymphovascular presence (T3Nx). The patient started with adjuvant concurrent chemo-radiation therapy and returned to regular hemodialysis.
We report a rare case of TCC in the pelvis of graft kidney with already advanced disease at diagnosis in a young KTR. For the early diagnosis of TCC in KTRs, exposure history to Chinese herb or analgesics should be investigated before KT and high risk population in KTRs should be tightly performed regular postoperative surveillance for TCC and considered of less calcineurin inhibitor-based immunosuppressant protocol.
肾移植(KT)是终末期肾病(ESRD)患者延长生存期和改善生活质量的治疗选择。尽管使用强效免疫抑制剂可提高肾移植受者(KTRs)的移植物存活率,但可能导致包括移行细胞癌(TCC)在内的恶性肿瘤发生。移植肾肾盂发生的TCC在KTRs中非常罕见。
一名40岁男性因恶心、呕吐和肉眼血尿就诊。11年前,他被诊断为病因不明的ESRD,1年后接受了来自其父亲的亲属活体肾移植。影像学检查发现移植肾肾盂有一个巨大的息肉样肿块,伴有肾盂肾盏扩张,主动脉腔静脉链有一个3.3厘米大小的结节,右髂血管链有一个2.5厘米大小的结节,诊断为TCC IV期。超声引导下对移植肾肾盂肿块进行经皮穿刺活检,显示为低级别尿路上皮细胞癌。进行了根治性移植肾输尿管切除术,组织病理学诊断证实为移植肾肾盂和输尿管腔的低级别尿路上皮癌,侵犯肾周脂肪和肾实质,伴有淋巴管浸润(T3Nx)。患者开始接受辅助同步放化疗,并恢复规律血液透析。
我们报告了一例年轻KTR中诊断时已为晚期疾病的移植肾肾盂TCC罕见病例。为早期诊断KTRs中的TCC,肾移植前应调查中草药或镇痛药暴露史,KTRs中的高危人群应严格进行TCC术后定期监测,并考虑采用较少基于钙调神经磷酸酶抑制剂的免疫抑制方案。